Evidence map›Paper›PMID 39825007›Full record

ArticleAbdominal radiology (New York)2025

Performance of MR fusion biopsy, systematic biopsy and combined biopsy on prostate cancer detection rate in 1229 patients stratified by PI-RADSv2 score on 3T multi-parametric MRI.

Hannah H Riskin-Jones, Alex G Raman, Rushikesh Kulkarni, Corey W Arnold, Anthony Sisk, Ely Felker, David S Lu, Leonard S Marks, Steven S Raman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hannah H Riskin-JonesUniversity of California, Los Angeles, Los Angeles, USA. hriskinjones@mednet.ucla.edu.
Alex G RamanUniversity of California, Los Angeles, Los Angeles, USA.
Rushikesh KulkarniUniversity of California, Los Angeles, Los Angeles, USA.
Corey W ArnoldUniversity of California, Los Angeles, Los Angeles, USA.
Anthony SiskUniversity of California, Los Angeles, Los Angeles, USA.
Ely FelkerUniversity of California, Los Angeles, Los Angeles, USA.
David S LuUniversity of California, Los Angeles, Los Angeles, USA.
Leonard S MarksUniversity of California, Los Angeles, Los Angeles, USA.
Steven S RamanUniversity of California, Los Angeles, Los Angeles, USA. sraman@mednet.ucla.edu.

Funding

Computational Feature Profiling and Modeling for Prostate Cancer Detection and Risk StratificationR01CA279666 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Corey Wells Arnold · 2024 to 2026
$1.9M
NCI NIH HHS R01 CA279666
6 · The paper itself

Abstract

purposeWe analyzed the additional value of systematic biopsy (SB) to MR-Ultrasound fusion biopsy (MRgFbx) for detection of clinically significant prostate cancer (csPCa), as increased sampling may cause increased morbidity. MATERIALS AND

methodsThis retrospective study cohort was comprised of 1229 biopsy sessions between July 2016 and May 2020 in men who had a Prostate Imaging-Reporting and Data System (PI-RADSv2) category ≥ 3 lesion on 3 Tesla multiparametric MRI (3TmpMRI) and subsequent combined biopsy (CB; MRgFbx and SB) for suspected prostate cancer (PCa). Cancer detection rates (CDR) were calculated for CB, MRgFbx and SB in the study cohort and sub-cohorts stratified by biopsy history and PI-RADSv2 category. For 927 men with unilateral MR-visible lesions, SB CDR was additionally calculated for contralateral (SBc) and ipsilateral (SBi) subcohorts.

resultsOn CB, the CDR for csPCa was 54.8% (673/1229). CDR for csPCa was significantly higher for MRgFbx (50.0%, CI 47.1-52.8%) compared to SB (35.3%, CI 32.6-38.1%) for all PI-RADSv2 ≥ 3 categories (p < .05). The MRgFbx CDR for PI-RADSv2 categories 3, 4, and 5 were 81.5%, 88.5%, and 95.6% respectively. For unilateral lesion cases, significantly more csPCa was detected in the SBi compared to the SBc subcohort (30.1% (279/927) vs. 10.4%, (96/927), p < 0.001). The combination of MRgFbx and SBi detected csPCa in 97.0% (480) of the 495 csPCa detected by CB.

conclusionMRgFbx had a higher CDR for csPCa than SB. While CB detected more csPCa than either method alone, in patients with a PI-RADSv2 category of 5, MRgFbx approximated the performance of CB. In unilateral lesion cases, SBc provided minimal added benefit.

Indexed as

Image-Guided BiopsyMagnetic Resonance ImagingMagnetic Resonance Imaging, InterventionalMultimodal ImagingMultiparametric Magnetic Resonance ImagingProstatic NeoplasmsAgedHumansMaleMiddle AgedProstateRetrospective StudiesUltrasonography, InterventionalBiopsyMRIProstate Cancer

Identifiers

PMID39825007
PMCPMC12267314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.